

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-5. (canceled).

6. (currently amended) The compound ~~according to Claim 1~~ which is selected from:

1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

1-{1-[4-(5-hydroxy-6-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[5-hydroxy-6-(1H-indol-3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one; and

1-(1-{4-[6-hydroxy-5-(1H-indol-3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

or a pharmaceutically acceptable salt thereof.

7. (currently amended) The TFA salts according to Claim ~~1~~ 6 selected from:


1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

1-{1-[4-(5-hydroxy-6-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[5-hydroxy-6-(1H-indol-3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one; and





1-(1-{4-[6-hydroxy-5-(1H-indol-3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one.

8. (currently amended) The compound according to Claim 1 which is selected from:




| <u>R''</u> | <u>R'''</u> |
|--|--|
| -OH | -CH ₂ CH(CH ₃) ₂ |
| -CH ₂ CH(CH ₃) ₂ | -OH |
| -OH | H |
| H | -OH |
| -OH | -CH ₂ Ph |
| -CH ₂ Ph | -OH |

| <u>R''</u> | <u>R'''</u> |
|---------------------|-------------|
| -CH ₂ Ph | -OH |

| | |
|---|---|
| -OH |  |
|  | -OH |
| -OH | -CH ₂ OH |
| -CH ₂ OH | -OH |
| -OH |  |
|  | -OH |
| -OH | -CH ₃ |
| -CH ₃ | -OH |




or a pharmaceutically acceptable salt or a stereoisomer thereof.

9. (currently amended) The TFA salt according to Claim + 8 selected from:



| <u>R''</u> | <u>R'''</u> |
|--|--|
| -OH | -CH ₂ CH(CH ₃) ₂ |
| -CH ₂ CH(CH ₃) ₂ | -OH |
| -OH | H |
| H | -OH |
| -OH | -CH ₂ Ph |
| -CH ₂ Ph | -OH |

| <u>R''</u> | <u>R'''</u> |
|---------------------|-------------|
| -CH ₂ Ph | -OH |
| -OH | |

| | |
|---|---|
|  | -OH |
| -OH | -CH ₂ OH |
| -CH ₂ OH | -OH |
| -OH |  |
|  | -OH |
| -OH | -CH ₃ |
| -CH ₃ | -OH |

or a stereoisomer thereof.

10. (canceled).

11. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 6.

12. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 8.

13-16. (canceled).

17. (currently amended) A method for treating ovarian, breast and prostate cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 6.

18. (currently amended) A method for treating ovarian, breast and prostate cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 8.

19-27. (canceled).